Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Rare Disease Plans Back On Track With Resubmission of Tafamidis

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer gained the therapy to treat a rare genetic neurologic disorder in its 2010 acquisition of folded protein company FoldRx.

You may also be interested in...



Pfizer, CFF Focus On Possible Combination Approach To Treating CF’s Underlying Cause

Building upon CFTR-focused drugs pioneered by Vertex’s Kalydeco, Pfizer will receive up to $58 million in R&D funding from the Cystic Fibrosis Foundation to bring new CF candidates into the clinic.

Pfizer Vyndaqel Advisory Committee Pits Orphan Flexibility Vs. Data Shortcomings

FDA finds much to question in a single pivotal trial of Pfizer’s orphan drug Vyndaqel (tafamidis meglumine) for familial amyloid polyneuropathy, but the ultra-orphan nature of the disease may outweigh those concerns.

Will Advisory Committee Review Vindicate Pfizer’s Vyndaqel?

Pfizer’s orphan drug tafamidis will be reviewed by FDA’s Peripheral and Central Nervous System Drugs Advisory Committee in May. The scheduling of a panel during a priority review is some indication FDA has concern, but the panels of outside experts are generally receptive to rare disease treatments.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073767

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel